Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "untreated asymptomatic brain metastases"

Imfinzi-Tarlatamab Combination Improves Overall Survival in Phase 3 ES-SCLC Trial

AstraZeneca and Amgen reported statistically significant improvements in overall and progression-free survival with Imfinzi plus tarlatamab versus Imfinzi alone in the Phase 3 DeLLphi-305 trial.

Untreated Asymptomatic Brain Metastases | 10/09/2026 | By News Bureau

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members